922727-92-2

Basic information

• Product Name: (1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarboxylic acid
• Synonyms: (1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarboxylic acid;Cyclopentanecarboxylic acid, 2-[(5-hexen-1-ylmethylamino)carbonyl]-4-hydroxy-, (1R,2R,4R)-;(1R,2R,4R)-2-[(5-Hexen-1-ylmethylamino)carbonyl]-4-hydroxycyclopentanecarboxylic acid;(1R,2R,4R)-2-(Hex-5-en-1-yl(methyl)carbamoyl)-4-hydroxycyclopentanecarboxylic acid
• CAS NO: 922727-92-2
• Molecular Formula: C₁₄H₂₃NO₄
• Molecular Weight: 269.33672
• EINECS: -0
• Mol File: 922727-92-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarboxylic acid(922727-92-2)
• EPA Substance Registry System: (1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarboxylic acid(922727-92-2)

Safety Data

• Hazardous Substances Data: 922727-92-2(Hazardous Substances Data)

Usage

General Description

The chemical "(1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarboxylic acid" is a compound with a complex structure. It consists of a cyclopentane ring with a hydroxyl group attached to the fourth carbon, and a carbamoyl group attached to the second carbon. Additionally, there is a hex-5-enyl group attached to the second carbon of the cyclopentane ring. (1R,2R,4R)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarboxylic acid belongs to the class of carboxylic acids and may have potential applications in the pharmaceutical or chemical industries. The specific configuration of the compound, as denoted by the (1R,2R,4R) prefix, indicates the spatial arrangement of the substituent groups on the cyclopentane ring.

Upstream product

• 28269-02-5 cis-4-oxo-1,2-cyclopentanedicarboxylic acid bis(methyl ester) 
• 67885-98-7 (1R,2R)-4-hydroxycyclopentane-1,2-dicarboxylic acid 
• 862259-02-7 trans-(3R,4R)-3,4-bis(methoxycarbonyl)cyclopentanol 
• 862175-17-5 N-methylhex-5-en-1-amine hydrochloride 
• 862174-60-5 (1R,4R,5R)-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxylic acid 
• 55863-02-0 N-methylhex-5-en-1-amine 
• 922520-05-6 2,2,2-trifluoro-N-(hex-5-enyl)-N-methylacetamide 
• 2695-47-8 6-Bromo-1-hexene 
• 1027355-52-7 3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid hex-5-enyl-methylamide 
• 862174-98-9 (1R,4R,5R)-N-(hex-5-en-1-yl)-N-methyl-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxamide 

Downstream Products

• 922727-93-3 (1R,2S)-1-{[(1R,2R,4S)-2-(hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid ethyl ester 

Relevant articles and documents

Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate

Synthesis of fluorocyclopropyl building blocks, which constitute the core of various therapeutic agents against the hepatitis C virus, is described. The relevant methyl α-amino-β-fluoro-β-vinylcyclopropanecarboxylate has been used as a key intermediate for the total synthesis of a fluorinated analogue of Simeprevir (TMC 435), a HCV NS3/4A protease inhibitor.

PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS

Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of Formula (I) and the salts and stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR7, -NH-SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1 -6alkyl, C3 -7cycloalkyl; n is 3, 4, 5, or 6; R4 is C1-6alkyl or C3-7cycloalkyl; R5 is hydrogen, halo, C1-6alkyl, hydroxy, C1 -6alkoxy, polyhaloC1 -6alkyl; R6 is hydrogen, C1-6alkoxy, mono- or diC1 -6alkylamino; or R5 and R6 may form a 5- or 6-membered unsaturated or partially unsaturated ring, optionally co mprising one or two selected from O, N and S; R7 is hydrogen; C3-7cycloalkyl optionally subst ituted with C1-6alkyl; or C1-6alkyl optionally subst ituted with C3 -7cycloalkyl; R8 is C3-7cycloalkyl optionally subst ituted with C1 -6alkyl; C1 -6alkyl optionally substituted with C3-7cycloalkyl; or -NR8aR8b; R8a and R8b are C1-6alkyl, or both may form a 5- or 6-membered saturated heterocyclic ring; pharmaceut ical compositions containing compounds (I) and processes for preparing compounds (I).